MPO and colitis: Treatment with the serine protease inhibitor UAMC-00050, started at week 2 after adoptive T cell transfer, showed no significant effect on the clinical disease score in colitis mice (Figure 2B; Supplementary Table S2), whereas it moderately but significantly decreased the colonoscopic, macroscopic and microscopic score at week 4, associated with a significant decrease in the myeloperoxidase activity and a small but significant decrease in the colonic weight/length ratio (Figures 2C–G, Figure 3).